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Immunopathology and Infectious Disease
Exacerbated Pathology of Viral Encephalitis in Mice
with Central Nervous System-Specific Autoantibodies
Renaud Burrer,* Michael J. Buchmeier,*
Tom Wolfe,† Joey P.C. Ting,* Ralph Feuer,*
Antonio Iglesias,‡ and Matthias G. von Herrath†
From the Molecular and Integrative Neurosciences Department,*
The Scripps Research Institute, La Jolla, California; the La Jolla
Institute of Allergy and Immunology,† Immune Regulation Lab,
La Jolla, California; and the Roche Center for Medical
Genomics,‡ Basel, Switzerland
We examine here the outcome of viral encephalomy-
elitis [mouse hepatitis virus (MHV) A59, Theiler’s en-
cephalomyelitis virus, and Coxsackievirus B3] in mice
with autoantibodies to a central nervous system
(CNS)-specific antigen, myelin oligodendrocyte glyco-
protein, that usually develop no clinical disease. Mor-
bidity and mortality of the acute viral CNS disease was
augmented by the presence of the autoantibodies in
all three viral infections. Transfer of serum contain-
ing the autoantibodies at the time of infection with
MHV was sufficient to reproduce the exacerbated dis-
ease. The presence of the autoantibodies was found to
result in increased infiltration of mononuclear cells
into the brain. Early demyelination was severely aug-
mented in brains and spinal cords of MHV-infected
mice with CNS-specific autoantibodies. The antibody-
mediated exacerbationwas shown to be independent of
the complement system but to require expression of Fc
receptors, because it was observed in C-3-deficient but
not in Fc receptor-deficient mice. Our study illustrates
the possibility that infections can lead to much more
profound immunopathology in the presence of an oth-
erwise latent autoimmune condition. (Am J Pathol 2007,
170:557–566; DOI: 10.2353/ajpath.2007.060893)
It is now well established in animal models that infectious
organisms can trigger or augment immune responses to
self-antigens, by mechanisms such as molecular mimicry
or bystander activation (see review1). However, autoim-
munity does not always result in clinically apparent dis-
ease, and cumulative infections by the same or unrelated
agents may be required to unmask a pre-existing auto-
immune process.1 Conversely, a viral infection could take
a worsened course in autoimmune-prone individuals. It
has been shown that infections can provoke relapses or
worsen autoimmune conditions in animal models.2–4 This
is consistent with reports showing that common infections
augment the risk for or the severity of relapses in multiple
sclerosis (MS) patients.5,6
The aforementioned animal reports all studied T-cell-
mediated autoimmune responses, but autoantibodies
also have an important pathogenic potential (see re-
view7). In the central nervous system (CNS), autoantibod-
ies to myelin components and to myelin oligodendrocyte
glycoprotein (MOG) in particular can play a damaging
role. MOG-specific antibodies have been shown to play a
major role in the murine model of MS, experimental au-
toimmune encephalomyelitis (EAE),8 and have been
clearly associated with demyelinating lesions in MS pa-
tients.9 They are thus likely to mediate some of the pa-
thology, at least in the subset of patients with lesions
presenting antibody depositions.10 However, the pres-
ence of antibodies specific for MOG or other CNS anti-
gens is detected not only in MS patients but also in
healthy subjects, albeit with a lower frequency,11 and it is
thus likely that additional triggers may be required for
disease development.
Litzenburger et al12 previously demonstrated that
transgenic mice, in which the rearranged VDJ region of a
MOG-specific monoclonal antibody H chain replaced the
germline JH locus [anti-MOG immunoglobulin (Ig)
“knock-in” mice, also referred to as THMOG mice in the
present report], exhibited an exacerbated form of EAE.
However, without additional autoantigenic immunization,
the THMOG mice do not develop spontaneous clinical
disease, despite the presence of autoreactive B cells and
the release of MOG-specific IgG and IgM in the serum.12
Because the transgenic B cells in THMOG can undergo
normal differentiation and maturation, autoantibodies of
different classes and subclasses, membrane-associated
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or secreted, are generated. Thus, all of the possible
interactions of the autoreactive Igs with the other effec-
tors of the immune system can occur in these mice.
Therefore, they constituted a good model to evaluate the
hypothesis that a viral infection of the CNS would lead to
worsened immunopathology and disease, if it were to be
superimposed on an underlying humoral autoimmune
condition.
The neurotropic strains of murine coronaviruses mouse
hepatitis virus (MHV) A59, MHV JHM, and related mu-
tants have provided an informative model for the patho-
genesis of virus-induced encephalitis and demyelination
(see reviews13,14). Mice infected with MHV A59 typically
undergo a brief period of acute encephalomyelitis fol-
lowed by an extended period of chronic demyelination.
During the acute phase of the infection, the virus can be
found in astrocytes, oligodendrocytes, and neurons.15 T
cells are responsible for the initial control of the infec-
tion,16 but antibodies are required for complete clear-
ance of the virus and prevention of re-emergence.17,18
During the second phase of the disease, macrophages19
but also CD420,21 and CD821 T cells have been shown
to mediate the demyelination.
We report here that intracranial infection of THMOG
mice with MHV A59 results in accelerated kinetics of
onset, severity of clinical disease, and increased death in
THMOG compared with wild-type mice. The exacerbation
of the CNS disease was shown to be transferable by the
autoantibodies and was observed in other models of viral
encephalitis as well. Immunohistochemical examination
of brain sections and fluorescence-activated cell sorting
analysis of infiltrating cells in brains showed an overall
increase of the number of mononuclear cells. Demyeli-
nation was found to be augmented in brains and spinal
cords of mice with anti-MOG antibodies. Fc receptor-
deficient mice were shown to be protected from the au-
toantibody-mediated enhanced pathology, indicating
that the mechanism for the exacerbation involved Fc-
mediated effects. Thus, autoantibodies specific for anti-
gens in the immunologically privileged CNS in combina-
tion with local, virally induced inflammation and tissue
destruction can lead to increased sensitivity of disease.
Materials and Methods
Mice
THMOG mice encode the rearranged cDNA of the patho-
genic MOG-specific monoclonal antibody 8.18C5 in
place of the germline JH locus.
12 This results in MOG-
binding Ig surface expression on about one-third of the B
cells that can undergo normal class-switching and secre-
tion and affinity maturation after encountering the anti-
gen.12 C57Bl/6 control mice were obtained from The
Scripps Research Institute breeding facility. CD4-KO and
CD8-KO mice obtained from Dan Littman (Sloan-Ketter-
ing Institute, New York, NY) and C-3-KO and inducible
NO synthase (iNOS)-KO mice purchased from the Jack-
son Laboratory (Bar Harbor, ME) (all on a C57Bl/6 back-
ground) were bred at Scripps. Fcer1-KO mice (583-M,
C57Bl/6 background) were purchased from Taconics
Transgenics (Germantown, NY). All experiments were
conducted in accordance with the Scripps Research In-
stitute Institutional Animal Care and Use Committee
guidelines.
Viruses
Mouse hepatitis virus-attenuated neurotropic isolate A-59
was grown on delayed brain tumor (DBT) cells. Theiler’s
murine encephalomyelitis virus (TMEV) Daniel’s strain ob-
tained from Dr. D. McGavern (The Scripps Research
Institute) was grown on BHK21 cells. Viral titers were
determined by plaque assay on DBT cells. Coxsackievi-
rus B3 was grown and titered as previously described.22
Pichinde virus stocks were grown and titrated on Vero
cells.
Induction of CNS Immune Pathology
Isoflurane-anesthetized mice were inoculated with 30 l
containing the virus diluted in sterile phosphate-buffered
saline (PBS), using a 27-gauge needle with no more than
2-mm penetration of the cranium just lateral of the mid-
line. Signs of clinical CNS disease were monitored daily
and scored using standards as described in Figure 1.
Serum from THMOG mice was obtained by retroorbital
bleeding or cardiac puncture and pooled to be used for
transfer experiments. Recipient animals received 500 l
of the serum pool intraperitoneally at the time of the viral
infection, whereas controls received the same volume of
normal mouse serum or in later repeat experiments, PBS,
because normal serum was found to have no measurable
effect on the course of the infection.
Histology
Mice were euthanized with an overdose of chloral hydrate
diluted in saline and perfused with 10 ml of 10% formalin.
After fixation overnight, brains and spinal cord paraffin-
embedded sections were stained by hematoxylin and
eosin (H&E) (to evaluate infiltration) and luxol fast blue
(for demyelination).
Flow Cytometry
Brains from PBS-perfused mice were mechanically dis-
rupted between frosted slides. The lipid components and
debris were removed after collagenase (Sigma C-6885)
treatment and centrifugation through Percoll (Sigma).
Brains of groups of five or six mice were pooled to obtain
enough mononuclear cells to assay. Fc receptors were
blocked (14-0161; eBiosciences, San Diego, CA), and
cells were stained with antibodies directly coupled to
fluorochromes. Data were acquired on a BD FACSCali-
bur. CD11b (for macrophages/microglia) or CD45 (for
the other cell types) cells were gated to analyze the
expression of specific markers. All antibodies were ob-
tained from eBiosciences.
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Statistical Analysis
Significance was evaluated using Mann-Whitney (for
day-by-day differences between clinical scores, viral
titers or ratio of areas affected by demyelination), Fish-
er’s exact test (for incidence of disease in the autoim-
mune mice when there was none in the control group),
or log-rank survival (for differences in mortality over
entire experiments) tests using the GraphPad/Instat
software.
Results
MHV-Induced Acute CNS Disease Is
Exacerbated in THMOG Transgenic Mice
THMOG and C57Bl/6 mice were infected with three
increasing doses of MHV, strain A59. Typical symp-
toms of encephalitis were observed in both groups and
for each of the viral doses. However, clinical signs of
CNS disease occurred earlier and were stronger in the
THMOG mice compared with Bl6 controls (Figure 1,
top). The three viral doses also resulted in an in-
creased death rate in THMOG mice in comparison with
controls (Figure 1, bottom).
The Enhanced Susceptibility to CNS Disease
after MHV Infection Can Be Transferred by Anti-
MOG Autoantibodies
To rule out that the enhanced disease observed in the
transgenic mice could have been caused by the absence
of a functional antibody repertoire or any other possible
genetic defect, we first examined the outcome of the CNS
infection by MHV A59 in heterozygous THMOG mice ob-
tained by backcrossing the transgenic mice with the
parental C57Bl/6 strain. The acute encephalitis was also
exacerbated in these mice compared with controls (Fig-
ure 2A), indicating that the aggravation of disease was
probably due to the presence of CNS-specific B cells or
autoantibodies.
We then examined whether the transgenic B cells, the
autoantibodies, or both were responsible for the in-
creased CNS disease. We first transferred purified
THMOG B cells to WT mice and observed some exacer-
bation of the CNS disease compared with controls receiv-
ing wild-type B cells, although to a much lesser extent
than in the original THMOG animals (data not shown).
However, when serum from uninfected THMOG mice was
transferred to wild-type recipients at the time of infection
with MHV, an exacerbation of CNS disease similar to the
levels found in MHV-infected THMOG mice was observed
(Figure 2B). In addition, transfer of Protein-A purified
Figure 1. The outcome of MHV A59 acute infection of the CNS is exacerbated in THMOG knock-in mice. Mice were observed and given a numerical score (top
panels) for behavioral signs of encephalitis (0, no detectable sign of disease; 1, ruffled fur; 2, slightly hunched back and ruffled fur; 3, very hunched back and
lethargy; and 4, death) daily during the acute infection phase in mice infected with increasing doses of virus (left to right). Data represent the average and standard
errors for each group. The bottom panels show the survival of the animals in the same experiments. *P  0.05; **P  0.01; ***P  0.001.
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antibodies from the serum of THMOG resulted in a com-
parable exacerbation of MHV-induced encephalitis as
the serum (data not shown). These studies clearly
mapped the cause for enhancement of the virally in-
duced CNS disease in THMOG mice to the anti-MOG
autoantibodies.
Anti-MOG Antibodies Exacerbate Viral
Encephalitis in Other Viral Models
We then tested the effects of the presence of the anti-MOG
antibodies in other nonlethal viral models of CNS infection to
determine whether viruses from different families and with
different degrees of pathogenicity could be exacerbated by
the presence of anti-MOG autoantibodies. Although no dif-
ference was observed in the clinically silent encephalitis
induced by 105 plaque-forming units (PFU) of Pichinde
virus, an exacerbation of the CNS disease by the autoanti-
bodies was observed in mice infected with both TMEV and
CV B3 (Table 1). C57Bl/6 are genetically resistant to TMEV
infection, ie, the virus replicates but does not cause detect-
able inflammation or demyelination,23 and as expected, no
behavioral signs of acute CNS disease were seen in the
control mice. However, 44% of the THMOG heterozygous
animals developed a clinically evident disease, and one-
half of the sick animals died within the 1st week (Table 1).
Likewise, no signs of disease could be observed in any of
the 2-week-old control pups infected with 103 or 104 PFU
CV B3, whereas 20 or 100% of the heterozygous autoim-
mune mice became sick, respectively (Table 1). This was
reflected by a profound difference in the weights of the two
groups when injected with 104 PFU CV B3: all of the pups
initially gained weight at an equal rate (111  3% in
THMOG versus 108 4% in controls at 5 days after infec-
tion). The transgenic animals then started to grow at a
slower rate and eventually lost weight, resulting in an aver-
age of 109  2% of their starting weight at day 10 after
infection, versus 137 1% in the controls (P 0.01, Mann-
Whitney test). These experiments show that the adverse
effects of pre-existing autoantibodies can have an impact
on the outcome of a variety of viral encephalitis. They also
show that exacerbation can occur over a large spectrum of
clinical manifestations of encephalitis: Autoantibodies can
transform a clinically silent infection into a symptomatic
disease (TMEV and CV B3), transform a mild CNS pathol-
ogy into a lethal one (MHV A59, 10 PFU), or accelerate the
clinical course (MHV A59, 1000 PFU).
Table 1. Outcome of Other Viral CNS Infections in Control and THMOG Heterozygous Mice
Virus
Dose
(PFU)
C57Bl/6 controls THMOG /
Clinical signs
Mortality
Clinical signs
Mortality (days)‡Incidence Score Incidence* Score (days)†
Pichinde 10E5 0/4 N.A. 0/4 0/4 N.A. 0/4
TMEV 10E5 0/5 N.A. 0/5 4/9 0.83  0.59 (5) 2/9 (5, 7)
CV B3 10E3 0/5 N.A. 0/5 2/5 0.70  0.19 (15) 1/5 (16)
10E4 0/5 N.A. 0/5 7/7§ 1.5  0.14 (9) 0/7
The viruses were injected i.c. at the indicated doses in 2-week-old (CV B3) or 6-week-old (Pichinde and TMEV) mice. The table summarizes the
follow-up of the clinical status and mortality in control (C57Bl/6) and autoimmune (heterozygous THMOG) animals. N.A., not applicable.
*Number of mice with detectable clinical disease over total number in each group.
†Highest average clinical score for each group, and the day after infection when it was observed.
‡Number of deaths over total number of animals studied and timing of death.
§P  0.01, Fisher’s exact test.
Figure 2. Autoantibodies account for the exacerbated viral encephalitis. A: Clinical disease and survival after intracranial (i.c.) inoculation of 10 PFU of MHV A59
in C57Bl/6 controls (black squares, plain lines) and THMOG heterozygous mice (open diamonds, dashed lines). B: Comparison of the viral encephalitis after
injection of 10 PFU of MHV A59 in C57Bl/6 that received serum of THMOG mice intraperitoneally at the time of infection (open diamonds, dashed lines) or
mock-treated controls (black squares, plain lines). *P  0.05; **P  0.01; ***P  0.001.
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Viral Replication of MHV in Mice with MOG-
Specific Antibodies
To test whether viral replication was required to trigger
disease in mice with CNS autoantibodies, we injected
5  105 PFU equivalent of UV-inactivated MHV A59,
which did not cause any detectable clinical disease in
homozygous THMOG mice over a 21-day period (n  2;
data not shown). Likewise, no sign of clinical disease was
detected in such mice on infection by 100 PFU of MHV
A59 via the intraperitoneal route (n  2; data not shown),
a dose that results in a clinically silent hepatitis with active
viral replication for over a week in C57Bl/6 mice (R.B. and
M.J.B., personal observations). Thus, neither the disrup-
tion of the blood brain barrier, viral antigens in the CNS,
nor infection of a peripheral organ elicited enhanced
immunopathology in THMOG mice, showing that active
viral replication in the CNS was required.
Viral titers in the brains of control C57Bl/6 mice and
mice with autoantibodies (THMOG homo- and heterozy-
gous mice and C57Bl/6 recipients of anti-MOG serum)
were then compared at different time points. No signifi-
cant difference was found in the titers in mice with auto-
antibodies compared with the controls from day 3 (data
not shown) up to days 5 and 6 (Figure 3) after the infec-
tion, which indicates that the virus replicates initially at
similar rates in all of the animals. However, although the
titers started to decrease in both groups at day 7, the
reduction of the viral load was less pronounced in mice
with anti-MOG autoantibodies compared with controls
(Figure 3). Thus, the ability to control the viral CNS infec-
tion is slightly impaired in the presence of the CNS
autoantibodies.
To exclude any systemic defect on the cytotoxic im-
mune response to MHV in the MOG-Ig mice, we com-
pared the frequencies of virus-specific CD8 T cells in
the spleen of controls and recipients of anti-MOG serum
by enzyme-linked immunospot (ELISPOT) assays, which
were performed as described previously.24 We found no
significant difference in the frequencies of purified CD8
cells that responded to the immunodominant MHV A59
epitope S598-605, which is located in the viral envelope
protein, at day 5 or 7 after infection (data not shown).
Thus, the autoantibodies did not alter the systemic anti-
viral cytotoxic immune response.
Infiltration Is Augmented in Mice with Anti-MOG
Autoantibodies
To study the mechanisms responsible for the autoanti-
body-mediated augmentation of viral encephalitis, we
chose a model that results in severe outcome in a major-
ity of the autoimmune mice while sparing most of the
control animals, and the following experiments have thus
all been performed with 10 PFU of MHV A59.
H&E-stained brain and spinal cord sections obtained
from controls and mice with autoantibodies were exam-
ined for the presence of infiltrating cells. The degree of
infiltration appeared to be augmented in mice with auto-
antibodies compared with control animals at days 7 to 9
after infection. Both the frequency of perivascular cuffing
and the number of infiltrating cells within inflammation
areas were higher in mice with autoantibodies compared
with controls (Figure 4, A–E). Morphologically, the infil-
trates appeared to be composed of mixed inflammatory
cell populations, with numerous neutrophils being seen
both in the controls and in the mice with autoantibodies
(Figure 4, F–G). To determine more precisely the nature
of the infiltrating cells, we performed flow cytometry ex-
periments on mononuclear cells purified from infected
brains. Enumeration of the purified cells from individual
brains confirmed the increased cellularity in the brains of
mice with autoantibodies (Figure 4H). The presence of
the autoantibodies resulted in no significant differences
in the numbers of T or B lymphocytes (Figure 4I). On the
contrary, the frequency of NK cells and blood-borne
macrophages was somewhat more elevated in mice with
autoantibodies (Figure 4I). Altogether, these results show
that brain infiltration of lymphocytes, and in particular
cells bearing Fc receptors, is augmented by the pres-
ence of anti-MOG antibodies during MHV A59
encephalitis.
Anti-MOG Antibodies Augment Demyelination in
MHV Infection
Both MHV A59 and anti-MOG antibodies (in EAE models)
can provoke demyelination on their own. To evaluate the
eventual additive effects of their joint presence in the
CNS, we examined sections from brains and spinal cords
of MHV-infected autoimmune and control mice for the
presence of demyelinating lesions at 7 to 9 days after
infection. The vast majority of the demyelinating areas
were found in the central white matter of the cerebellum,
in the brainstem, and in the region surrounding the third
ventricle, both in controls and in mice with autoantibod-
ies, but the extent of the lesions was found to be aug-
mented in the latter group. In wild-type mice brains, small
lesions were detected in a majority of the animals, but the
Figure 3. Infectious virus levels in the brain. Brains obtained from control
mice (black diamonds) or animals with autoantibodies (white squares,
homozygous THMOG; white triangles, heterozygous THMOG; white cir-
cles, wild-type recipients of THMOG serum) infected with 10 PFU of MHV
A59 were obtained at various time points after inoculation. Viral titers from
homogenized half-brains were determined by plaque assay. Data are pooled
from six independent experiments. Each point represents an individual
animal, and black lines represent the average for each group. *P  0.05.
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mice with autoantibodies displayed lesions that were
both more widespread in the tissue and larger in size
(Figure 5A, left panel). This difference was even more
pronounced in spinal cords, with only a small subset of
the control mice displaying lesions at 7 to 10 days after
infection [Figure 5, A (right panel) and B], whereas most
animals with autoantibodies showed heavy demyelination
in coronal (Figure 5A, right panel) and longitudinal (Fig-
562 Burrer et al
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ure 5, C and D) sections. These results show that demy-
elination plays a role in the enhancement of the CNS
disease in our model.
The Autoantibody-Mediated Exacerbation of the
CNS Disease Is T-Cell-Complement- and
iNOS-Independent
To investigate the possible involvement of different
effectors that have been associated with demyelination
and CNS pathology in other models, we compared the
outcome of CNS infection by MHV A59 in the presence
or absence of anti-MOG antibodies in different KO
mouse models. In the absence of either the CD4 or
the CD8 T cells, control of the MHV A59 infection of
the CNS is impaired. The mortality was found to be
much higher for the control group in CD8 KO mice than
what we had observed in WT C57Bl/6 mice. However,
an exacerbation of the disease in the presence of
autoantibodies was still observed in the absence of
Figure 4. Infiltration is augmented in the presence of anti-MOG antibodies. A–E: Representative H&E-stained sections from brains of MHV A59-infected mice.
Moderate inflammation, with some perivascular cuffing (black arrows), was detected in the brains of control mice (A and B, both obtained from different
moribund animals 8 days after the infection). The degree of infiltration was augmented in all mice with autoantibodies (E, recipient of anti-MOG serum at day
8, clinical score 2) or earlier in the course of infection (C and D, obtained from moribund mice at day 7 after infection). Black bar  0.2 mm. F and G: Close-up
pictures from sections A and D, respectively, showing mixed inflammatory cell infiltrates.White arrowheads indicate some individual polymorphonuclear cells,
which also can be found in large cluster in G. Some cells with lymphocyte morphology (black arrows) can also be seen in infiltrates in both groups of mice.
Black bar  0.05 mm. H: Total numbers of mononuclear cells purified from individual brains collected from control (black bars) or recipient of anti-MOG serum
(open bars) mice 5 or 6 days after infection with MHV A59. Average and SE, n  6 (day 50) or 13/14 (day 6) per group. I: Brains from control mice (average
clinical score, 0.56  0.12, n  8) and recipients of anti-MOG serum (1.78  0.18, n  7) were collected 6 days after MHV A59 infection. Mononuclear cells were
purified from each individual brain, counted, pooled by group, and stained for flow cytometry analysis. The graph shows the average number of T lymphocytes
(CD4CD8-cd45 and CD4-CD8cd45), B lymphocytes (B220CD19CD45), NK cells (NK1.1CD45), neutrophils (Ly6GCD45), blood-borne macro-
phages (CD11bF4/80CD45HIGH), and resident microglia (CD11bF4/80CD45LOW) per animal. Similar results were obtained in additional independent
experiments performed at days 5, 6, and 7 after infection.
Figure 5. Demyelinating lesions in the brains and spinal cords of MHV-A59-infected mice. Luxol Fast Blue-stained tissue sections from control and autoimmune
mice were examined for demyelination. A: Quantification of demyelinating lesions in control (black diamonds) and autoimmune (empty symbols) mice. A
square grid was applied to sagittal brain sections (left) and coronal spinal cord sections (right), and results are expressed as the percentage of the total quadrants
displaying lesions in each individual animal. Differences were statistically significant at day 7 for both organs. *P  0.05. **P  0.01. B and C: Representative
pictures of spinal cords (longitudinal sections) from a control animal (B) and a C57Bl/6 recipient of anti-MOG serum (C) both obtained at day 8 after infection
with 10 PFU of MHV A59. Note the massive infiltration in the lesion in C. Black bars  0.2 mm. D: The reconstituted picture shows demyelinating lesions
(arrowheads) spreading over the entire length of a spinal cord longitudinal section, obtained from the same animal as in C. It is representative of mice with
autoantibodies at 7 to 9 days after infection, whereas all of the control mice in this study had little or no lesions in the spinal cord. Black bar  1 mm.
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CD4 or CD8, both at the clinical (data not shown) and
survival (Table 2) levels. Likewise, the exacerbation of
CNS disease was still evident in the absence of a
functional complement system in C-3 KO mice (Table
2). Last, in mice deficient in iNOS, all of the controls
survived, whereas all of the mice transferred with anti-
MOG serum succumbed to the infection (Table 2).
These results show that neither CD4 T cells, CD8 T
cells, complement, nor iNOS alone is responsible for
the autoantibody-mediated pathology.
Fc Receptors Are Required for Enhanced CNS
Disease in MHV-Infected MOG-Ig Mice
To determine whether the pathogenic effects of the au-
toantibodies required Fc receptors, we compared the
outcome of the viral encephalitis in the presence or ab-
sence of the CNS-specific autoantibodies in mice defi-
cient in Fc receptors FcRI, FcRIII, and FcR. As shown
on Figure 6, the clinical status of both groups was found
to be similar, whereas MHV A59-infected wild-type
C57Bl/6 mice showed the expected exacerbation when
transferred with the serum from the same pool. The ex-
periment in the Fc receptor-deficient mice was repeated
with two more mice per group, and as the absence of
exacerbation was confirmed on day 7 after infection (clin-
ical scores of 1.0 and 2.0 versus 1.0 and 1.0 for the
controls and the mice transferred with autoimmune se-
rum, respectively), the animals were sacrificed to obtain
histological data. Sections from brains and spinal cords
showed no difference in the level of infiltration or demy-
elination between the controls and the recipients of the
anti-MOG serum (data not shown). These experiments
clearly demonstrate that cells bearing Fc receptors are
involved in the augmented morbidity and mortality ob-
served in MHV-infected mice in the presence of the anti-
MOG antibodies.
Discussion
We show here that the moderate CNS disease after in-
fection of mouse CNS by MHV A59 is dramatically ag-
gravated by the pre-existence of a humoral autoimmune
response against a CNS antigen (MOG). This finding is
not limited to this single virus, because we found that
both TMEV and CV B3, used in conditions in which the
control animals develop no disease at all, also trigger
pathology in mice with autoantibodies. Because the three
viruses have low or no genetic relation, this indicates that
the mechanism responsible for the augmented disease is
very unlikely to involve cross-reactivity between the self-
antigen and the pathogen. More likely, the inflammatory
milieu generated by the infections allows the entry of the
autoantibody in the otherwise secluded CNS compart-
ment and attracts other immune mediators that can con-
tribute to the immunopathology.
We found that infiltration of mononuclear cells in the
brain after MHV infection was augmented by the pres-
ence of autoantibodies affecting all infiltrating cell types.
In particular, an augmentation of the frequency of neu-
trophils and blood-borne macrophages was detected in
both the recipients of anti-MOG serum transfer and the
heterozygous THMOG mice compared with the controls.
Anti-MOG antibodies, and 8.18C5 in particular, have
been shown to augment demyelination in the EAE mod-
el.9,11,12 Likewise, we have shown here that both the
incidence and the intensity of early demyelination were
augmented in the brain and spinal cord of mice with
anti-MOG autoantibodies. The localization of the areas
affected in the brain was found to be similar in the control
mice and in the animals with autoantibodies. Interest-
ingly, a similar pattern was described in experiments
performed by transfusing a MOG-specific monoclonal
antibody along with MOG-specific T cells in rats.25 These
histopathological patterns are reminiscent of the multifo-
cal lesions throughout the brain and spinal cord found in
EAE in animal models and in acute disseminated en-
cephalomyelitis in humans.
Our results show that neither CD4 nor CD8 T cells
alone are responsible for the aggravated disease, al-
though both of these T-cell subsets have been shown to
be the important effectors responsible for demyelination
in CNS infection by MHV.20,21 The increased pathology
observed in our autoimmune mice after viral infection
Figure 6. Anti-MOG antibodies do not exacerbate encephalitis in Fc recep-
tor-deficient mice. Although all mice showed clinical signs of CNS infection,
the intensity of MHV-induced disease was not affected by the transfer of
anti-MOG autoantibodies in mice deficient in Fc receptors, and all of the mice
survived the experiment in both groups (left, n  3/group). MHV A59-
infected wild-type mice transferred with the same serum pool displayed the
normal exacerbation at the time they were sacrificed for a flow cytometry
experiment (right, n 6/group). *P 0.05. The experiment was repeated as
indicated in the main text section, confirming the absence of antibody-
mediated pathology in the Fc receptor-deficient mice.
Table 2. Autoantibodies Exacerbate MHV A59 Encephalitis
in KO Mice Models
Mock transfer Anti-MOG serum transfer
CD4 KO 2/12 9/13*
CD8 KO 6/10 9/10†
C-3 KO 3/11 8/11*
iNOS KO 0/6 6/6‡
The mortality of CD4 KO, iNOS KO, and C-3 KO mice infected with
10 PFU of MHV A59 was significantly augmented in the presence of
anti-MOG antibodies. The absence of CD8 cells results in higher
fatalities in the control group than in wild-type mice, but some
exacerbation was still observed upon transfer of autoimmune serum.
*P  0.05.
†P  0.063.
‡P  0.001.
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thus results from a distinct autoantibody-mediated mech-
anism rather than from exacerbation of the damage
caused directly by the virus or by the antiviral immune
response. The augmented disease is transferred by se-
rum containing the autoantibodies and is Fc receptor-
mediated. In further support of this hypothesis, viral
replication was similar in controls and mice with autoan-
tibodies during the first 6 days of the infection and was
only significantly higher in the autoimmune mice on day 7
after infection. ELISPOT and intracellular cytokine data
indicated, however, that the viral-specific cytotoxic re-
sponse was not significantly impaired in those mice, nei-
ther at the systemic nor at the local level.
Complement deposition has been found in lesions in
MS patients,10 and the demyelination potential of myelin-
specific antibodies has been shown to correlate with
complement-binding ability.26 The experiments per-
formed in C-3 KO mice indicate that in our model, com-
plement has little or no involvement in the autoantibody-
mediated pathology. Another possible source of CNS
damage can be NO,27 which has been shown to be
involved in MS lesions.28 However, NO plays little role in
MHV-induced demyelination, even though it can damage
neurons during the infection,29,30 and iNOS-deficient
mice have been reported to have a better survival rate
than wild-type animals.29 In accordance with this litera-
ture, we found control iNOS KO mice to survive the in-
fection better than the C57Bl/6 animals. However, our
experiments showed that iNOS was not involved in the
antibody-mediated pathology, because all of the KO
mice that were transfused with autoimmune serum suc-
cumbed to the infection. On the contrary, we found that a
deficiency in cellular Fc receptors FcRI and FcRIII was
sufficient to abrogate completely the autoantibody-medi-
ated pathology at both clinical and histological levels.
This indicates that neutrophils, macrophages, or NK cells
are responsible for the autoantibody-mediated pathol-
ogy. Based on these results and on the characteristics of
the mononuclear infiltration in the autoimmune mice, we
propose that cells of the monocyte/macrophage/micro-
glia lineage, neutrophils, or NK cells are responsible for
the autoantibody generated damage, through a mecha-
nism that does not involve complement or iNOS release.
The existence of cross-reactivity between antibodies
binding to viral and self-antigens has been extensively
investigated, but only a few reports, to our knowledge,
have focused on the in vivo interplay of noncross-reactive
autoantibodies and viral infections. The -herpesvirus
HV-68 has been shown to provoke relapses of experi-
mental autoimmune arthritis in mice.31 Lactate dehydro-
genase-elevating virus and MHV each resulted in dra-
matic exacerbation of the pathology and mortality in a
mouse model of antibody-triggered autoimmune hemo-
lytic anemia.32 Likewise, both lactate dehydrogenase-
elevating virus and MHV infections also provoke a severe
thrombocytopenia in mice treated with anti-platelet anti-
bodies at otherwise nonpathogenic doses.33 To our
knowledge, the present report constitutes the first de-
scription of a similar phenomenon in the CNS compart-
ment in an animal model. Our findings are consistent with
previous studies performed with human patients, which
suggest a correlation between the presence of autoanti-
bodies in the cerebrospinal fluid (CSF) and the outcome
of encephalitis. Desai et al34 reported that fatal outcome
in a cohort of 72 patients with Japanese encephalitis virus
infection was significantly associated to the presence of
CSF autoantibodies, against neurofilament proteins in
particular. Likewise, Matsui et al35 found that in a group of
14 patients with viral encephalitis of undefined etiology,
three of the four patients with CNS autoantibodies were
among the total of five individuals with an unfavorable
outcome. Both of these studies were performed with pa-
tients enrolled at the time that pathology was declared,
making it impossible to determine whether the autoanti-
bodies existed before the CNS infection or if they ap-
peared as a consequence of the encephalitis. Likewise,
there was no way to determine whether the autoantibod-
ies had a direct role in the unfavorable outcomes or were
merely an associated marker. However, in view of the
results obtained in the present study, it is very possible
that the autoimmune status of those patients had an
adverse effect on the evolution of their CNS disease.
In conclusion, our study strengthens the hypothesis
that in individuals with pre-existing autoantibodies, with
or without clinical autoimmune disease, certain viruses
can have a heightened pathogenic potential. It reinforces
the concept that pathogens that are unrelated to the initial
development of the autoimmune condition may cause
exacerbation episodes by modifying the local or systemic
environment. The model of an autoimmune “fertile field”
proposes that autoreactive T cells are first generated by
some infections through molecular mimicry or bystander
mechanisms but may remain nonpathogenic for ex-
tended periods and that unrelated viruses or bacteria
may be responsible for triggering the actual autoimmune
pathology.1,4 In this model, Koch’s postulates (one dis-
ease/one pathogen) are not strictly respected, which may
explain why it has been so difficult to associate a single
organism to a given autoimmune disease.
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